Design
Review
Authors
Loading...
May inform glucose counterregulation mechanisms; leaves open IGFBP-1 as biomarker or target pending prospective trials.
Key points are not available for this paper at this time.
Lee et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: